Adoptive cellular immunotherapy for the treatment of malignant gliomas

Critical Reviews in Oncology/Hematology

Volumn 39, Issue 1-2, 2001, Pages 31-42

  Hayes, Roberta L ^a   Arbit, Ehud ^a   Odaimi, Marcel ^a   Pannullo, Susan ^a   Scheff, Ronald ^a   Kravchinskiy, Dmitriy ^a   Zaroulis, Charles ^a  

^a STATEN ISLAND UNIVERSITY HOSPITAL   (United States)

Author keywords

Eosinophils; Glioblastoma; IL 2; Immunotherapy; Interleukin 2; LAK; Lymphokine activated killer cells; Malignant glioma; Survival

Indexed keywords

CORTICOSTEROID; DEXAMETHASONE; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; BRAIN TUMOR; CANCER SURGERY; CANCER SURVIVAL; CATHETER; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; EOSINOPHILIA; FEVER; GLIOBLASTOMA; HEADACHE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEUKAPHERESIS; LYMPHOCYTIC INFILTRATION; LYMPHOKINE ACTIVATED KILLER CELL; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECURRENT CANCER; TUMOR NECROSIS;

EOSINOPHILS; GLIOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 0034978815     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(01)00122-6     Document Type: Conference Paper

References (76)

1. Cancer Statistics, 1998
2. Malignant astrocytic neoplasms: classification, pathologic anatomy, and response to treatment
3. Surgical resection and radiation therapy versus biopsy and radiation therapy in the treatment of glioblastoma multiforme
4. Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme. Results of three consecutive radiation therapy oncology group (RTOG) clinical trials
5. Reoperation for glioblastoma
6. Reoperation in the treatment of recurrent intracranial malignant gliomas
7. Survival and functional status after resection of recurrent glioblastoma multiforme
8. Therapy of adult malignant brain tumors: What have the clinical trials taught us?
9. Comparisons of carmustine, procarbazine, and high dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma
10. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse
11. Improved long-term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma
12. The cellular immunotherapy of primary brain tumors
13. Selected immunotherapy studies of the interferons and IL-2/LAK
14. Structure and expression of a cloned cDNA for human interleukin-2
15. Site-specific mutagenesis of the human interleukin-2 gene: structure-function analysis of the cysteine residues
16. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in patients with metastatic cancer
17. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and Interleukin-2 or high-dose interleukin-2 alone
18. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer
19. Cancer biotherapy with interferon, interleukin-2 and tumor-derived activated cells (TDAC)
20. Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group Experience
21. Combination biotherapy utilizing interleukin-2 and alpha interferon in patients with advanced cancer: a National Biotherapy Study Group Trial
22. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. A National Biotherapy Study Group trial
23. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor
24. Lymphokine-activated killer cell phenomenon. Lysis of natural-killer cell-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes
25. Adoptive chemotherapy of a syngeneic murine lymphoma using longterm lymphoid cell lines expanded in T cell growth factor
26. Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin-2
27. Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2
28. Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2
29. Recombinant interleukin-2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells
30. The antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo
31. Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2
32. In vitro cytolysis of primitive neuroectodermal tumors of the posterior fossa (medulloblastoma) by lymphokine-activated killer cells
33. Cytolytic effects of autologous lymphocyte-activated killer cells on organotypic multicellular spheroids of gliomas in vitro
34. Effect of corticosteroids on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice
35. Lymphokine-activated killer cells with interleukin-2: dose toxicity and localization in isolated perfused rat lungs
36. Interleukin-2 and autologous lymphokine-activated killer cells in the treatment of malignant glioma
37. Preliminary clinical trial of immunotherapy for malignant glioma
38. Adoptive immunotherapy for recurrent glioblastoma multiforme using lymphokine activated killer cells and recombinant interleukin-2
39. Intratumoral LAK cell and interleukin-2 therapy of human gliomas
40. Complete remission of recurrent glioblastoma multiforme following local infusions of lymphokine activated killer cells: Case report
41. Generation of stimulated, lymphokine activated T killer (T-LAK) cells from the peripheral blood of normal donors and adult patients with recurrent glioblastoma
42. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy
43. Treatment of recurrent malignant glioma by repeated intracerebral injections of human recombinant interleukin-2 alone or in combination with systemic interferon-alpha. Results of a phase I clinical trial
44. Therapy of recurrent high grade gliomas with surgery, and autologous mitogen activated IL-2 stimulated killer (MAK) lymphocytes: I. Enhancement of MAK lytic activity and cytokine production by PHA and clinical use of PHA
45. Local immunotherapy of recurrent glioblastoma multiforme by intracerebral perfusion of interleukin-2 and LAK cells
46. Treatment of human glioblastoma by specific immunotherapy
47. A loco-regional immunotherapy with recombinant interleukin-2 and adherent lymphokine-activated killer cells (A-LAK) in recurrent glioblastoma patients
48. Immunotherapy of malignant gliomas
49. Interferon alpha-2a and external beam radiotherapy in the initial management of patients with glioma: A pilot study of the National Biotherapy Study Group
50. MRI of recurrent high-grade astrocytomas after intralesional immunotherapy
51. Treatment of recurrent glioma with intracavitary alloreactive cytotoxic T lymphocytes and interleukin-2
52. Cellular therapy of brain tumors: clinical trials
53. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK)
54. Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report
55. Immunological fluctuations during intrathecal immunotherapy in three patients affected by CNS tumours disseminating via CSF
56. Scintigraphy with In-111 labeled lymphokine-activated killer cells of malignant brain tumor
57. Large-scale production of human lymphokine activated killer cells for use in adoptive immunotherapy
58. An improved method for the generation of human lymphokine activated killer cells
59. Interleukin 2 administered in vivo induces the growth of cultured T cells in vivo
60. Augmentation of the antitumor therapeutic efficacy of long-term cultured T lymphocytes by in vivo administration of purified interleukin-2
61. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes
62. Antitumor activity against established intracerebral gliomas exhibited by cytotoxic T lymphocytes, but not by lymphokine-activated killer cells
63. Recurrent malignant gliomas: survival following interstitial brachytherapy with high-activity iodine-125 sources
64. High activity iodine-125 interstitial implant for gliomas
65. A phase I dose escalation study of hypofractionated stereotactic radiotherapy as salvage therapy for persistent or recurrent malignant glioma
66. Treatment of recurrent glioblastoma multiforme using fractionated stereotactic radiosurgery and concurrent paclitaxel
67. Activation of eosinophils in cancer patients treated with IL-2 and IL-2 generated lymphokine-activated killer cells
68. Eosinophils and serum eosinophilic cationic proteins in interleukin-2 based immunotherapy for cancer
69. Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C
70. Evidence for eosinophil activation in cancer patients receiving recombinant inteleukin-4: effects of interleukin-4 alone and following inteleukin-2 administration
71. The eosinophil granule proteins in serum, but not the oxidative metabolism of the blood eosinophils, are increased in cancer
72. The eosinophil-mediated antitumor activity of interleukin-4
73. Tumour-associated eosinophilia: a review
74. Tumor-associated eosinophilotactic factor
75. Morphologic evidence suggestive of host-tumor cell interactions in vivo in human cancer patients